Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of 5-Amino-1MQ and NAD+ — mechanism, side effects, legal status, and pricing.
5-Amino-1MQ is a small heterocyclic molecule (not a peptide) that acts as a selective, membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT). It is under preclinical investigation for obesity and non-alcoholic fatty liver disease. It is not FDA-approved and has not completed human clinical trials; it is commonly tracked alongside peptides because grey-market vendors sell it for metabolic protocols.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all living cells, not a peptide. It is classified here alongside peptides for user convenience in the anti-aging / metabolic category. NAD+ plays a central role in cellular energy metabolism and redox reactions and is studied for its involvement in mitochondrial function, DNA-damage signaling via sirtuins and PARPs, and age-associated metabolic decline. IV NAD+ is not FDA-approved for any clinical indication; it is administered off-label through compounding pharmacies and functional-medicine clinics with limited rigorous outcome data.
5-Amino-1MQ
NAD+
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
5-Amino-1MQ
NAD+
COA corpus from Disclosed Labs — independently tested batches only.
5-Amino-1MQ
80
COAs
99.5%
Avg purity
12
Labs
NAD+
146
COAs
99.4%
Avg purity
15
Labs
Neelakantan et al. (2018, Biochem Pharmacol, PMID 29155147) reported that 5-Amino-1MQ and related selective, membrane-permeable methylquinolinium NNMT inhibitors reversed high-fat-diet-induced obesity in mice, reducing body weight, white adipose mass, adipocyte size, and plasma cholesterol without changing food intake. A separate NNMT inhibitor program (Kannt et al., 2018, Sci Rep, PMID 29483571, JBSNF-000088) produced similar metabolic effects in rodents. Dimet-Wiley et al. (2022, Sci Rep, PMID 35013352) reported microbiome changes with NNMT inhibition plus low-fat diet in DIO mice, and Babula et al. (2024, Diabetes Obes Metab, PMID 39161060) showed 5A1MQ dose-dependently limited weight and fat gain and reduced NAFLD-like liver pathology in DIO mice. No human clinical trials of 5-Amino-1MQ have been completed or published as of 2026; grey-market oral protocols are not clinically validated.
Key references
The strongest human evidence for raising circulating NAD+ comes from oral-precursor trials. A randomized, double-blind, placebo-controlled study of nicotinamide riboside combined with pterostilbene (NRPT) showed sustained dose-dependent increases in whole-blood NAD+ over 8 weeks in healthy adults (Dellinger et al., npj Aging and Mechanisms of Disease, 2017). A Yoshino/Baur/Imai review summarizes the biology and emerging therapeutic potential of NR and NMN, including preclinical healthspan data in aged mice (Cell Metabolism, 2018). Direct IV NAD+ has only small pilot pharmacokinetic data: Grant et al. infused 750 mg over 6 hours in 8 healthy men and documented altered plasma and urine NAD+ metabolome without clinical-outcome endpoints (Frontiers in Aging Neuroscience, 2019). No adequately powered RCTs support IV or SubQ NAD+ for anti-aging, cognition, addiction, or Parkinson's disease; clinic marketing claims outrun the published outcome evidence.
5-Amino-1MQ and NAD+ are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs